This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Badia, E. Articles by Pons, M. Search for Related Content PubMed PubMed Citation Articles by Badia, E. Articles by Pons, M.

Hydroxytamoxifen Induces a Rapid and Irreversible Inactivation of an Estrogenic Response in an MCF-7-derived Cell Line

Centre de Recherche de l'Institut National de la Santé et de la Recherche Médicale, 70 rue de Navacelles, 34090 Montpellier, France

The MVLN cell line was established in our laboratory from MCF-7 cells by stable transfection with the luciferase gene under the control of an estrogen-responsive element from the Xenopus vitellogenin A2 gene. This cell line allowed us to visualize the induction by hydroxytamoxifen of a heterogeneity in the cell population with regard to the expression of the luciferase gene. Treated cells lost their estradiol-inducible luciferase activity, progressively and irreversibly; the luciferase expression of 80% of the cells was irreversibly inactivated by a 12-day hydroxytamoxifen treatment. We showed that this inactivation process was specific for an estrogenic response and was mediated by the estrogen receptor. Tamoxifen itself gave rise to such an inactivation, whereas other compounds belonging to the triphenylethylenic family but differently substituted on the ethylenic carbon and the ICI 164,384 compound were not as efficient. This irreversible inactivation was accompanied by a sharp decrease in the luciferase mRNA level; however, the estrogen receptor function and the cellular transcriptional machinery were not affected by the treatment. Although this antiestrogen treatment neither affected the estrogen-dependent cell growth nor irreversibly inhibited the expression of the natural pS2 gene, these results highly suggest that long-term antiestrogen therapy may lead to some heterogeneity in tumor cells throughout the course of patient treatment.

¹ To whom requests for reprints should be addressed.

Received 6/14/94. Accepted 9/14/94.

This article has been cited by other articles:

				E. Demirpence, A. Semlali, J. Oliva, P. Balaguer, E. Badia, M.-J. Duchesne, J.-C. Nicolas, and M. Pons An Estrogen-responsive Element-targeted Histone Deacetylase Enzyme Has an Antiestrogen Activity That Differs from That of Hydroxytamoxifen Cancer Res., November 15, 2002; 62(22): 6519 - 6528. [Abstract] [Full Text] [PDF]

				E. Badia, M.-J. Duchesne, A. Semlali, M. Fuentes, C. Giamarchi, H. Richard-Foy, J.-C. Nicolas, and M. Pons Long-Term Hydroxytamoxifen Treatment of an MCF-7-derived Breast Cancer Cell Line Irreversibly Inhibits the Expression of Estrogenic Genes through Chromatin Remodeling Cancer Res., August 1, 2000; 60(15): 4130 - 4138. [Abstract] [Full Text]